ODI Pharma AB Statistics
Total Valuation
ODI Pharma AB has a market cap or net worth of SEK 28.23 million. The enterprise value is 26.74 million.
Market Cap | 28.23M |
Enterprise Value | 26.74M |
Important Dates
The last earnings date was Thursday, August 28, 2025.
Earnings Date | Aug 28, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
ODI Pharma AB has 18.33 million shares outstanding. The number of shares has increased by 20.56% in one year.
Current Share Class | 18.33M |
Shares Outstanding | 18.33M |
Shares Change (YoY) | +20.56% |
Shares Change (QoQ) | +15.29% |
Owned by Insiders (%) | 90.92% |
Owned by Institutions (%) | n/a |
Float | 1.66M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 9.08 |
PB Ratio | 34.67 |
P/TBV Ratio | 34.67 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -4.55 |
EV / Sales | 8.60 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.16
Current Ratio | 1.16 |
Quick Ratio | 1.09 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -7.07 |
Financial Efficiency
Return on equity (ROE) is -417.65% and return on invested capital (ROIC) is -232.44%.
Return on Equity (ROE) | -417.65% |
Return on Assets (ROA) | -36.39% |
Return on Invested Capital (ROIC) | -232.44% |
Return on Capital Employed (ROCE) | -643.04% |
Revenue Per Employee | 3.11M |
Profits Per Employee | -5.88M |
Employee Count | 1 |
Asset Turnover | 0.35 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, ODI Pharma AB has paid 4,211 in taxes.
Income Tax | 4,211 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.20% in the last 52 weeks. The beta is 0.53, so ODI Pharma AB's price volatility has been lower than the market average.
Beta (5Y) | 0.53 |
52-Week Price Change | -69.20% |
50-Day Moving Average | 1.74 |
200-Day Moving Average | 2.51 |
Relative Strength Index (RSI) | 46.61 |
Average Volume (20 Days) | 4,417 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ODI Pharma AB had revenue of SEK 3.11 million and -5.88 million in losses. Loss per share was -0.32.
Revenue | 3.11M |
Gross Profit | 833,115 |
Operating Income | -5.24M |
Pretax Income | -5.87M |
Net Income | -5.88M |
EBITDA | -5.23M |
EBIT | -5.24M |
Loss Per Share | -0.32 |
Balance Sheet
The company has 1.48 million in cash and n/a in debt, giving a net cash position of 1.48 million or 0.08 per share.
Cash & Cash Equivalents | 1.48M |
Total Debt | n/a |
Net Cash | 1.48M |
Net Cash Per Share | 0.08 |
Equity (Book Value) | 814,122 |
Book Value Per Share | 0.04 |
Working Capital | 809,638 |
Cash Flow
Operating Cash Flow | -5.37M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross margin is 26.78%, with operating and profit margins of -168.31% and -189.01%.
Gross Margin | 26.78% |
Operating Margin | -168.31% |
Pretax Margin | -188.87% |
Profit Margin | -189.01% |
EBITDA Margin | -168.25% |
EBIT Margin | -168.31% |
FCF Margin | n/a |
Dividends & Yields
ODI Pharma AB does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -20.56% |
Shareholder Yield | n/a |
Earnings Yield | -20.83% |
FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |